TBRG vs MTEX vs HIMS vs NATR vs TDOC

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -10. 7% for Mannatech, Incorporated (MTEX). Mannatech, Incorporated (MTEX) offers the better valuation at 3. 5x trailing P/E, making it the more compelling value choice. Analysts rate Nature's Sunshine Products, Inc. (NATR) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Mannatech, Incorporated (MTEX) is the cheapest at 3.

5x versus TruBridge, Inc. at 88. 9x. On forward P/E, TruBridge, Inc. is actually cheaper at 10. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: NATR returned +180. 2% versus TDOC's -41. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mannatech, Incorporated (MTEX) is the lower-risk stock at 0.

27β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 797% more volatile than MTEX relative to the S&P 500. On balance sheet safety, Nature's Sunshine Products, Inc. (NATR) carries a lower debt/equity ratio of 12% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -10. 7% for Mannatech, Incorporated (MTEX). On earnings-per-share growth, the picture is similar: Mannatech, Incorporated grew EPS 210. 0% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -7. 9% for Teladoc Health, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TBRG leads at 9. 7% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — MTEX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, TruBridge, Inc.

(TBRG) trades at 10. 1x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 41. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mannatech, Incorporated (MTEX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

27)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTEX: -35. 2%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TBRG (Healthcare) and MTEX (Consumer Defensive) and HIMS (Healthcare) and NATR (Consumer Defensive) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TBRG is a small-cap quality compounder stock; MTEX is a small-cap deep-value stock; HIMS is a small-cap high-growth stock; NATR is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.